ÂÜÀòÂÒÂ×

Steven Almo is the Chairman of the Department of Biochemistry at Albert Einstein College of Medicine, where he is a Professor of Biochemistry and of Physiology & Biophysics. Dr. Almo holds the Wollowick Family Foundation Chair in Immunology and is Director of Einstein’s Macromolecular Therapeutics Development Facility, a resource dedicated to the development and optimization of protein-based therapeutics. Dr. Almo is recognized for his broad contributions to structural biology and has published more than 300 papers. His laboratory has played key roles in the development and implementation of high-throughput approaches for protein production, structure determination, and functional annotation. Dr. Almo received his Ph.D. in Biophysics from Harvard University, while working with Greg Petsko in the Chemistry Department at MIT, and is best known for his high-resolution structural and biochemical characterization of the CTLA-4 and PD-1 immune checkpoint proteins and their respective ligands. The strategy for clonal-specific T cell modulation, which underlies Cue Biopharma’s therapeutic discovery pipeline, was developed in Dr. Almo’s laboratory.